On the 9th of May of 2018, the addendum H18-01 to the report H16-02C “Ultrasound-guided high-focused ultrasound (USgHIFU) therapy for malignant neoplasms of the pancreas” was published by the Institute for Quality and Efficiency in Health Care (IQWiG). Previously, at the beginning of March of 2018, the Federal Joint Committee (G-BA) has commissioned to IQWiG to provide the addendum H18-01 to the report H16-02C in accordance with § 137h of SGB V. The main purpose of the addendum was to identify the existing studies for the following topics:
- USgHIFU as an additional tumor-modifying therapy or palliative therapy for patients with inoperable pancreatic cancer compared to chemotherapy or chemoradiotherapy
- USgHIFU as an additional tumor-modifying therapy or palliative therapy for patients with inoperable pancreatic carcinoma compared to a stand-alone palliative care if chemotherapy or chemoradiotherapy cannot be used
IQWiG has published the following conclusions:
- According to the results of conducted systematic literature search, several completed studies were identified: 2 - for the first topic and 1 – for the second topic. However, the identified studies do not contain the relative evidence of benefits, which could be considered for this report
- Relevant ongoing studies in a framework of the researched topics were not identified
In summary, the result of the §137h assessment H18-01 was not changed by the studies additionally transmitted.
See full details in German here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.